Genvor Incorporated Appoints Donald Kalkofen as Chief Financial Officer

Genvor Incorporated announced the appointment of Donald Kalkofen as its Chief Financial Officer, effective May 18, 2026. Mr. Kalkofen, 63, brings over 20 years of CFO experience in biotechnology, financial services, and technology sectors, with expertise in capital raises, SEC reporting, and investor relations. He previously served as CFO for Alpha Cognition, Inc. and Protagonist Therapeutics Inc. Concurrently, the Company entered into a service agreement with Wave Financial Consulting LLC, owned by Mr. Kalkofen, for his CFO services. The agreement includes monthly compensation of $6,250, deferred compensation of $7,750 per month, and stock options for 575,000 shares, with specific vesting conditions tied to continued service and a potential stock exchange listing. An amended and restated agreement dated May 21, 2026, modified terms including the duration and payment of deferred compensation, and outlined a plan for equity compensation subject to board and shareholder approval. The company also issued a press release on May 21, 2026, regarding Mr. Kalkofen's appointment.